OUTPATIENT SYSTEMIC HIGH-DOSE METHOTREXATE AS CNS PROPHYLAXIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Ruben Fernandez, 214768

OUTCOME OF A 10-YEAR POPULATION-BASED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE FIRST-LINE, REFRACTORY AND RELAPSED SETTING: ‘REAL-WORLD’ DATA IDENTIFY SUBGROUPS IN NEED OF NEW THERAPIES

EHA Library, Hilde van der Galien, 214769

LOW SUNLIGHT EXPOSURE AT TIME OF DLBCL DIAGNOSIS MAY BE ASSOCIATED WITH INFERIOR SURVIVAL IN ELDERLY WOMEN

EHA Library, Anna Elinder Camburn, 214770

THE PROGNOSTIC ROLE OF 18FDG-PET/TAC AT THE END OF FIRST LINE CHEMO-IMMUNOTHERAPY IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: A MONOCENTRIC STUDY ON 308 PATIENTS.

EHA Library, Elena Maiolo, 214771

AN INCREASED RISK OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN CHILDREN AFTER CARDIAC TRANSPLANTATION FOR CONGENITAL HEART DISEASE

EHA Library, Ugonna Offor, 214773

FACTOR VIII RECOVERY TEST IN PERIOPERATIVE MANAGEMENT OF ORTHOPEDIC SURGERY IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A

EHA Library, Jae Joon Han, 214775

REAL WORLD SWITCHING FROM CONVENTIONAL FVIII PRODUCTS TO RFVIIIFC IN FRANCE, GERMANY, ITALY AND THE UK

EHA Library, Persefoni Kritikou, 214777

MYPKFIT HEMOPHILIA EXPERIENCE IN PEDIATRIC CASES

EHA Library, Selin Aytac, 214778

CHALLENGES OF MANAGEMENT OF REFUGEE CHILDREN WITH CONGENITAL FACTOR DEFICIENCIES

EHA Library, Gul Ozdemir, 214779

NOVEL MUTATIONS IN PATIENTS WITH TELOMEROPATHIES

EHA Library, Monika Haubitz, 214781

CLINICAL AND MORPHOLOGIC PREDICTORS OF OUTCOME IN APLASTIC ANEMIA PATIENTS TREATED WITH ELTROMBOPAG

EHA Library, Bruno Fattizzo, 214784

A COMPARATIVE STUDY OF INTENSIVE IMMUNOSUPPRESSIVE THERAPY AND HAPLOIDENTICAL TRANSPLANTATION FOR YOUNG SEVERE APLASTIC ANEMIA

EHA Library, Miao Chen, 214785

EFFECT OF ECULIZUMAB ON TRANSFUSION NEEDS IN PNH PATIENTS WITH AND WITHOUT TRANSFUSION HISTORY

EHA Library, Alexander Röth, 214787

RESULTS OF COBALT, A PHASE II CLINICAL TRIAL OF COVERSIN IN PNH

EHA Library, Anita Hill, 214790

INTERROGATION OF HAEMATOPOIETIC BONE MARRROW PROGENITORS FOR DRIVER MUTATIONS OF CHRONIC LYMPHOCYTIC LEUKAEMIA

EHA Library, David Bruce, 214792

SMG1 LOSS ENHANCES MTOR SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

EHA Library, Tara Roberts, 214793

PAPTP LEADS TO NEOPLASTIC CELL APOPTOSIS IN THE EΜ-TCL1 CHRONIC LYMPHOCYTIC LEUKEMIA MOUSE MODEL

EHA Library, Filippo Severin, 214795

CLL-DERIVED EXOSOMES REPROGRAM THE PHOSPHOPRTEOMICS LANDSCAPE OF ENDOTHELIAL CELLS.

EHA Library, Lian Lipshtein, 214798

T CELL CLONAL DYNAMICS ARE ASSOCIATED WITH CLINICAL RESPONSE AFTER LENALIDOMIDE CONSOLIDATION TREATMENT IN CLL

EHA Library, Anastasia Hadzidimitriou, 214800

EVOLUTION OF GENOMIC ABNORMALITIES DURING CLL DISEASE COURSE IS ASSOCIATED WITH TELOMERE LENGTH CHANGES

EHA Library, Helena Olbertova, 214802

NOTCH1, TP53, SF3B1, ATM AND BIRC3 GENE MUTATIONS ARE ASSOCIATED WITH A WORSE OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13Q LOSSES

EHA Library, Ana E Rodríguez-Vicente, 214803

CIRCULATING SEX HORMONES AND NUCLEAR HORMONE RECEPTOR EXPRESSION ARE ASSOCIATED WITH TREATMENT-FREE SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Katrina Vanura, 214806

LOW CATALASE EXPRESSION CONFERS REDOX HYPERSENSITIVITY AND IDENTIFIES AN INDOLENT CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Maria SCUPOLI, 214808

STAT3 AND STAT5B MUTATIONS IN LARGE GRANULAR LYMPHOCYTES LYMPHOCYTOSIS/LEUKEMIAS: DIAGNOSTIC AND PROGNOSTIC VALUE

EHA Library, Alberto Orfao, 214809

CG’806, A NON-COVALENT PAN-FLT3/PAN-BTK INHIBITOR, EXHIBITS UNIQUE BINDING TO WILD TYPE AND C481S MUTANT BTK AND GREATER POTENCY THAN IBRUTINIB AGAINST MALIGNANT B CELLS

EHA Library, Hongying Zhang, 214812

SALVAGE USE OF IBRUTINIB AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA OR MANTLE CELL LYMPHOMA : A STUDY ON BEHALF OF THE SFGM-TC AND THE EBMT

EHA Library, Mauricette Michallet, 214815

IMPACT OF TP53-MUTATED CLONE SIZE ON OUTCOME OF RELAPSED/REFRACTORY (R/R) CLL PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB WITHIN THE PHASE 3 MURANO STUDY

EHA Library, Arnon Kater, 214818

SAFETY ANALYSIS OF VENETOCLAX AND IBRUTINIB FOR PREVIOUSLY TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FIRST INTERIM ANALYSIS FROM THE PHASE II VISION HO141 TRIAL

EHA Library, Carsten Niemann, 214819

REAL-WORLD RESULTS ON IBRUTINIB IN RELAPSED / REFRACTORY CLL: 30-MONTH FOLLOW-UP OF 95 SWEDISH PATIENTS TREATED IN A COMPASSIONATE USE PROGRAM

EHA Library, Maria Winqvist, 214824

ANALYSIS OF SUSTAINED HEMATOLOGIC IMPROVEMENT WITH IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA

EHA Library, William Wierda, 214825

REAL WORLD TREATMENT PERSISTENCE OF AUSTRALIAN IBRUTINIB PATIENTS IN A NAMED PATIENT PROGRAM

EHA Library, Constantine Tam, 214826

THE EFFICACY OF DUVELISIB MONOTHERAPY FOLLOWING DISEASE PROGRESSION ON OFATUMUMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL OR SLL IN A PHASE 3 CROSSOVER EXTENSION STUDY

EHA Library, Peter Hillman, 214827

EFFECTIVENESS OF IBRUTINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA IN DAILY PRACTICE IN THE NETHERLANDS: A NATIONWIDE POPULATION-BASED COHORT STUDY

EHA Library, Lina van der Straten, 214829

RAPID DOSE ESCALATION OF VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PREVIOUSLY TREATED WITH B-CELL RECEPTOR INHIBITOR THERAPY

EHA Library, Kristin Koenig, 214830

IMMUNOMODULATORY EFFECTS OF IFN-ΑLPHA ON T AND NK CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN DEEP MOLECULAR RESPONSE IDENTIFY POTENTIAL CANDIDATES FOR TREATMENT DISCONTINUATION

EHA Library, Massimo Breccia, 214833

NK-CELLS AND LOSS OF MOLECULAR RESPONSE AFTER TKI DISCONTINUATION IN CML PATIENTS

EHA Library, Yulia Davydova, 214835

MYELOID CELL POPULATION DYNAMICS IN TKI-TREATED CML

EHA Library, Sieghart Sopper, 214838

THE EFFECT OF PREGNANE X RECEPTOR SNP AND TKI TROUGH CONCENTRATION ON CLINIC RESPONSE AND TOXICITY AMONG CHINESE CML PATIENTS.

EHA Library, Jiang Zhiping, 214839

WT1 EXPRESSION PREDICTS THE RESPONSIVENESS OF CHRONIC MYELOID LEUKEMIA TO FIRST LINE THERAPY OF TYROSINE KINASE INHIBITOR

EHA Library, Eleonora Toffoletti, 214840

BOSUTINIB VERSUS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN THE BFORE TRIAL: 24-MONTH FOLLOW-UP

EHA Library, Carlo Gambacorti-Passerini, 214842

VARIATION IN LIMIT OF BLANK FOR BCR-ABL1 DETECTION BETWEEN LABORATORIES IMPACTS ON SCORING OF DEEP MOLECULAR RESPONSE

EHA Library, Helen White, 214845

FIRST INTERIM ANALYSIS OF THE RUSSIAN MULTICENTER PROSPECTIVE STUDY RU-SKI: DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND DEEP MOLECULAR RESPONSE

EHA Library, Ekaterina Chelysheva, 214847

ALLOGENEIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA IN THE TKI ERA: POPULATION BASED DATA FROM THE SWEDISH CML REGISTRY.

EHA Library, Anna Lübking, 214849

ADDRESSING THE DIAGNOSTIC GAPS IN PYRUVATE KINASE (PK) DEFICIENCY. CONSENSUS RECOMMENDATIONS ON THE DIAGNOSIS OF PK DEFICIENCY

EHA Library, Paola Bianchi, 214853

ACTIVATE: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AG-348 IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED

EHA Library, Marie-Hélène Jouvin, 214855

PYRUVATE KINASE DEFICIENCY IN JAPAN: A SUMMARY OF CLINICAL FEATURE, LABORATORY DATA AND ENZYMATIC DIAGNOSIS

EHA Library, Taiju Utsugisawa, 214856

ACTIVATE-T: A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AG-348 IN REGULARLY TRANSFUSED ADULTS WITH PYRUVATE KINASE DEFICIENCY

EHA Library, Marie-Hélène Jouvin, 214857

HIGH SUCCESS RATE OF TARGETED NEXT GENERATION SEQUENCING FOR THE DIAGNOSIS OF PATIENTS WITH RARE CONGENITAL ANEMIAS

EHA Library, Orna Steinberg Shemer, 214859

DIAGNOSIS OF RARE CONGENITAL HEMOLYTIC ANEMIAS ENABLED BY NEXT GENERATION SEQUENCING PANEL

EHA Library, Paola Bianchi, 214860

REPORT OF THE FIRST CASE OF HEREDITARY SPHEROCYTOSIS DUE TO A LARGE DELETION OF THE SPTA1 GENE

EHA Library, Patricia Aguilar-Martinez, 214862

CLINICAL CHARACTERISTICS OF PATIENTS WITH RED CELL PYRUVATE KINASE DEFICIENCY IN GERMANY

EHA Library, Paraskevi Klothaki, 214863

ANTI-CD19 CAR T-CELL THERAPY IN ADULTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL MALIGNANCIES AS A BRIDGE TO ALLOGENEIC TRANSPLANTATION – THE EXPEIENCE OF A SINGLE CENTER

EHA Library, Abraham Avigdor, 214866

EARLY MRD NEGATIVITY PREDICTS DEEPENING MYELOMA RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS TREATED WITH BB2121 ANTI-BCMA CAR T CELLS.

EHA Library, Nikhil Munshi, 214867

FIRST-LINE THERAPY WITH DONOR DERIVED HCMV-SPECIFIC T CELLS PROMOTES ANTIVIRAL IMMUNITY BY RESTORING THE QUANTITY AND FUNCTION OF RECIPIENT’S ENDOGENOUS HCMV-SPECIFIC T CELLS AFTER ALLO-HSCT

EHA Library, Xiangyu Zhao, 214868

CLINICAL CHARACTERISTICS AND OUTCOMES OF BURKITT LYMPHOMA IN A DEVELOPING COUNTRY

EHA Library, Vanderson Rocha, 214772

ASSESSMENT OF IMMUNE FUNCTION BEFORE AND AFTER TREATMENT WITH RECOMBINANT FACTOR VIII FUSED WITH FC FRAGMENTS

EHA Library, Stephanie Png, 214774

PREDICTION OF INHIBITORS IN HAEMOPHILIA PATIENTS BY SCORE IN ONE CENTER

EHA Library, Oleksandra Stasyshyn, 214776

PROTEIN EXPLORER IN THE CONTEXT OF OVERLAP OF BONE MARROW FAILURE DISORDERS

EHA Library, Ayodele Alaiya, 214780

RA101495, A SUBCUTANEOUSLY-ADMINISTERED PEPTIDE INHIBITOR OF COMPLEMENT COMPONENT C5, FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: PHASE 2 RESULTS

EHA Library, Anita Hill, 214782

DIFFICULTIES IN DIAGNOSIS AND MANAGEMENT IN PATIENTS WITH CYCLIC NEUTROPENIA

EHA Library, Cornelia Zeidler, 214783

EFFECTIVENESS OF ECULIZUMAB IN PNH PATIENTS RECEIVING CONCOMITANT IMMUNOSUPPRESSIVE THERAPY

EHA Library, Anita Hill, 214786

PROGNOSTIC SIGNIFICANCE OF RENAL DYSFUNCTION DURING THE CLINICAL COURSE IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A KOREAN MULTICENTER STUDY

EHA Library, Yeung-Chul Mun, 214788

COMPLEMENT ACTIVATION AND EXACERBATION OF HAEMOLYSIS SECONDARY TO RESPIRATORY VIRAL INFECTIONS IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH) PATIENTS TREATED WITH ECULIZUMAB

EHA Library, Ioanna Lazana, 214789

THE INCIDENCE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELL CLONES IN THE NORDIC COUNTRIES

EHA Library, Christian Kjellander, 214791

TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER CHEMOIMMUNOTHERAPY AND IBRUTINIB

EHA Library, Luca Vincenzo Cappelli, 214794

OVERTIME ASSESSMENT OF EPIGENETIC PROFILES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY

EHA Library, Maria Tsagiopoulou, 214796

JAK/SYK INHIBITION IS VITAL TO PREVENT B CELL RECEPTOR SIGNALING AND ITS REGULATION BY THE TUMOUR MICROENVIRONMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Andrew J. Steele, 214797

CHRONIC LYMPHOCYTE LEUKEMIA CELLS SHARE A UNIQUE CIRCULAR RNA EXPRESSION PATTERN

EHA Library, Oshrat Raz, 214799

PREVALENCE AND PROGNOSTIC IMPACT OF THE IGLV3-21 G110R MUTATION IN CLL – A PATHOBIOLOGICAL REDEFINITION OF THE UNFAVORABLE CLL SUBTYPE II

EHA Library, Hendrik VEELKEN, 214801

CHARACTERIZATION OF A NOVEL ENTITY IN CLL: SYMPTOMATIC BRONCHIAL INVOLVEMENT; A STUDY OF THE FRENCH INNOVATIVE LEUKEMIA ORGANIZATION (FILO) GROUP

EHA Library, Morgane Nudel, 214804

GENETIC ABERRATIONS AND PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED CHEMOIMMUNOTHERAPY (FCR/BR): CLINICAL PRACTICE EXPERIENCE

EHA Library, Michaela Spunarova, 214805

DESIGN AND MINION TESTING OF A NANOPORE SEQUENCING SPECIFIC GENE PANEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Francesco ALBANO, 214807

T-PLL CELLS RESEMBLE MEMORY-TYPE T-CELLS WITH ABERRANT EFFECTOR FUNCTIONS IMPLICATING A LEUKEMOGENIC COOPERATION OF TCL1A WITH TCR SIGNALING

EHA Library, Sebastian Oberbeck, 214810

INTEGRATED GENETIC PROFILES OF T-PLL IMPLICATE A TCL1/ATM-CENTERED MODEL OF ABERRANT DNA DAMAGE RESPONSES

EHA Library, Alexandra Schrader, 214811

DISTINCT IMMUNE SIGNATURES IN CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTER’S SYNDROME

EHA Library, Yucai Wang, 214813

DURABILITY OF RESPONSE TO VENETOCLAX (VEN) IN PATIENTS WITH CLL RELAPSED/REFRACTORY TO IBRUTINIB AND/OR IDELALISIB

EHA Library, John C. Byrd, 214814

MANAGEMENT, ADVERSE EVENTS, AND OUTCOMES OF 282 CLL PATIENTS (PTS) TREATED WITH VENETOCLAX (VEN) IN THE REAL WORLD

EHA Library, Chadi Nabhan, 214816

IBRUTINIB FOR FIRST-LINE TREATMENT OF OLDER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): A 4-YEAR EXPERIENCE FROM THE RESONATE-2 STUDY

EHA Library, Jan Burger, 214817

EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: UPDATED RESULTS FROM THE NCRI RIALTO TRIAL.

EHA Library, Andrew Pettitt, 214820

OBINUTUZUMAB PRE-INDUCTION ABROGATES HIGH TUMOR LYSIS RISK OF VENETOCLAX IN TREATMENT NAÏVE FCR-UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A PLANNED INTERIM ANALYSIS.

EHA Library, Mark David Levin, 214821

CONTINUING REMISSIONS AFTER VENETOCLAX AND OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND COEXISTING MEDICAL CONDITIONS

EHA Library, Kirsten Fischer, 214822

TWO-COHORT, PHASE II STUDY IN R/R CLL (COSMOS): FIRST PRELIMINARY SAFETY AND EFFICACY RESULTS OF MOR208 TREATMENT IN COMBINATION WITH IDELALISIB IN PATIENTS WHO DISCONTINUED PRIOR IBRUTINIB THERAPY

EHA Library, Wojciech Jurczak, 214823

A PHASE 1 DOSE ESCALATION STUDY OF ARQ 531 IN SELECTED PATIENS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

EHA Library, Jennifer Woyach, 214828

INDIRECT TREATMENT COMPARISON OF VENETOCLAX PLUS RITUXIMAB WITH B-CELL RECEPTOR INHIBITORS IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Anthony Mato, 214831

INHIBITION OF NUCLEOCYTOPLASMIC EXPORT ENHANCES SELECTIVE ELIMINATION OF LEUKEMIC STEM CELLS IN CHRONIC MYELOID LEUKEMIA

EHA Library, Michael W Deininger, 214832

IDENTIFICATION OF GENES DIFFERENTLY EXPRESSED BETWEEN BONE MARROW CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA AT DIAGNOSIS VS. 12 MONTHS OF FIRST-LINE NILOTINIB TREATMENT

EHA Library, Roberto Cairoli, 214834

POLYMORPHISMS IN MULTIDRUG RESISTANCE TRANSPORTER GENES AFFECT THE DURATION OF MOLECULAR RESPONSE TO NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Federica Loscocco, 214837

LONG-TERM TREATMENT-FREE REMISSION (TFR) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FOLLOWING FRONTLINE (1L) NILOTINIB (NIL): RESULTS FROM ENESTFREEDOM

EHA Library, Giuseppe Saglio, 214841

PREVALENCE AND OUTCOMES OF UNCOMMON BCR-ABL FUSION TRANSCRIPTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DATA FROM A SINGLE CENTER

EHA Library, Ya-Zhen Qin, 214843

UPDATED RESULTS FROM THE ONGOING PHASE I STUDY OF PF-114 MESYLATE IN PATIENTS WITH CML WITH FAILURE OF PRIOR TKI THERAPY

EHA Library, Anna turkina, 214844

DIGITAL PCR IN PH+ CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF “STABLE” DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION

EHA Library, Michele Malagola, 214846

RESULTS OF TREATMENT OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PREGNANCY IN ACCORDANCE WITH THE LEUKEMIC BURDEN AND TERM OF PREGNANCY (THE LET SCHEME)

EHA Library, Ekaterina Chelysheva, 214848

LONG-TERM TREATMENT-FREE REMISSION (TFR) FOLLOWING SECOND-LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 144-WK RESULTS

EHA Library, Hughes Tim, 214850

NILOTINIB VERSUS NILOTINIB COMBINED TO PEGYLATED-INTERFERON ALFA 2A IN FIRST-LINE CHRONIC PHASE CML PATIENTS. UPDATED INTERIM ANALYSIS OF A PHASE III TRIAL

EHA Library, Franck Emmanuel Nicolini, 214851

THE VALUE OF BCR-ABL1 QPCR LEVEL AND DOUBLING TIME (DT) TO PREDICT SUCCESSFUL TREATMENT-FREE REMISSION AFTER IMATINIB DISCONTINUATION: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB (TRAD) TRIAL

EHA Library, Dennis Kim, 214852

GENETIC MARKERS AND NEW TARGET GENES IN THE DIAGNOSIS OF RARE ANAEMIAS

EHA Library, Juan-Luis Vives Corrons, 214854

CLASSIFYING, SHARING AND REVIEWING GENETIC VARIANTS ASSOCIATED WITH RED CELL DISORDERS

EHA Library, Philip Davidson, 214858

NEXT GENERATION SEQUENCING FOR DIAGNOSIS OF INHERITED HEMOLYTIC ANEMIAS

EHA Library, Jorge M. Nieto, 214861

ANTITUMOR ACTIVITY BY TEGS: ALPHA/BETA T CELLS ENGINEERED TO EXPRESS A DEFINED GAMMA/DELTA TCR IN A 3D BONE MARROW NICHE MODEL OF MULTIPLE MYELOMA

EHA Library, Jurgen Kuball, 214864

LENALIDOMIDE AND PROGRAMMED DEATH-1 BLOCKADE SYNERGISTICALLY ENHANCES THE EFFECTS OF DENDRITIC CELL VACCINATION IN A MODEL OF MURINE MYELOMA

EHA Library, Je-Jung Lee, 214865